DOI: https://dx.doi.org/10.18565/pharmateca.2022.4.33-43
М.С. Новикова, О.М. Котешкова, М.Б. Анциферов
Эндокринологический диспансер ДЗМ, Москва, Россия
1. Lingvay I., Greenberg M., Gallo S., et al. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substud. Randomized Controlled Trial. Diab Obes Metab. 2021;23(7):1640-51. Doi: 10.1111/dom.14385. 2. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diab Care. 2020;43:S98-110. Doi: 10.2337/dc20-S009. 3. Davies M.J., D’Alessio D.A., Fradkin J., et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association the Study of Diabetes (EASD). Diab Care. 2018;41:2669-701. Doi: 10.2337/dci18-0033. 4. Filippas-Ntekouan S., Filippatos T.D., Elisaf M.S. SGLT2 inhibitors: are they safe? Postgrad. Med. 2018;130:72-82. Doi: 10.1080/00325481.2018.1394152. 5. Hsia D.S., Grove O., Cefalu W.T. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diab Obes. 2017;24:73-9. Doi: 10.1097/ MED.0000000000000311. 6. Thomas M.C. Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol Rev. 2016;12:249-55. Doi: 10.2174/1573403x12666160606120254. 7. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60:850- 86. Doi: 10.1053/j.ajkd.2012.07.005. 8. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28. Doi: 10.1056/NEJMoa1504720. 9. Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. Doi: 10.1056/NEJMoa1611925. 10. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57. doi: 10.1056/ NEJMoa1812389. 11. Packer M., Anker S.D., Butler J., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. doi: 10.1056/NEJMoa2022190. 12. Perkovic V., Jardine M.J., Neal B., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306. doi: 10.1056/NEJMoa1811744. 13. Heerspink H.J.L., Stefa nsson B.V, Correa-Rotter R., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. doi: 10.1056/NEJMoa2024816. 14. Cannon C.P., Pratley R., Dagogo-Jack S., et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425-35. doi: 10.1056/NEJMoa2004967. 15. Cosentino F., Cannon C.P., Cherney D.Z.I., et al. Efficacy of ertugliflozin on heart failurerelated events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: Results of the VERTIS CV trial. Circulation. 2020;142:2205-15. doi: 10.1161/CIRCULATIONAHA.120.050255. 16. Cherney D.Z.I., Charbonnel B., Cosentino F., et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetol. 2021. 17. Blonde L., Brunton S.A., Chava P., et al. Achievement of Target A1C by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both (Randomized Controlled Trials and Clinical Practice. Diab Spectr. 2019;32:93-103. doi: 10.2337/ds17-0082. 18. Meneghini L.F., Sullivan S.D., Oster G., et al. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. Diab Obes Metab. 2020;22(11):2004-2012. Doi: 10.1111/ dom.14152. 19. Dalal M.R., Grabner M., Bonine N., et al. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physicianperceived barriers to achieving glycemic targets. Diab Res Clin Pract. 2016;121:17-26. Doi: 10.1016/j.diabres.2016.08.004. 20. Cannon C.P., McGuire D.K., Pratley R., et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11-23. Doi: 10.1016/j. ahj.2018.08.016. 21. Petersen M.C., Shulman G.I. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98:2133-223. Doi: 10.1152/ physrev.00063.2017. 22. Vallon V., Thomson S.C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetol. 2017;60:215- 25. Doi: 10.1007/s00125-016-4157-3. 23. Neal B., Perkovic V., de Zeeuw D., et al. Efficacy and safety of canagliflozin, an inhibitor of sodiumglucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diab Care. 2015;38:403-11. Doi: 10.2337/dc14- 1237. 24. Rosenstock J., Jelaska A., Zeller C., et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo- controlled trial. Diab Obes Metab. 2015;17:936- 48. Doi: 10.1111/dom.12503. 25. Rosenstock J., Jelaska A., Frappin G., et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diab Care. 2014;37:1815-23. Doi: 10.2337/dc13- 3055. 26. Wilding J.P., Woo V., Soler N.G., et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405- 15. Doi: 10.7326/0003-4819-156-6201203200-00003. 27. Wilding J.P., Woo V., Rohwedder K., et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diab Obes Metab. 2014;16:124-36. Doi: 10.1111/dom.12187. 28. Vasilakou D., Karagiannis T., Athanasiadou E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and metaanalysis. Ann Intern Med. 2013;159:262-74. Doi: 10.7326/0003-4819-159-4-201308200-00007. 29. European Medicines Agency. SteglatroTM summary of product characteristics. URL: https://www.ema. europa.eu/en/documents/product-information/ steglatro-eparproduct-information_en.pdf. Accessed December 15, 2020. 30. Food and Drug Administration. SteglatroTM prescribing information. URL: https://www. accessdata. fda.gov/drugsatfda_docs/ label/2017/209803s000lbl.pdf. Accessed December 15, 2020. 31. Dagogo-Jack S., Liu J., Eldor R., et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo- controlled randomized study. Diab Obes Metab. 2018;20:530-40. Doi: 10.1111/dom.13116. 32. Grunberger G., Camp S., Johnson J., et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diab Ther. 2018;9:49- 66. Doi: 10.1007/s13300-017-0337-5. 33. Hollander P., Liu J., Hill J., et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diab Ther. 2018;9:193-207. Doi: 10.1007/s13300-017- 0354-4. 34. Miller S., Krumins T., Zhou H., et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diab Ther. 2018;9:253-68. Doi: 10.1007/s13300-017- 0358-0. 35. Pratley R.E., Eldor R., Raji A., et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diab Obes Metab 2018;20:1111-20. Doi: 10.1111/dom.13194. 36. Rosenstock J., Frias J., Pall D., et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diab Obes Metab. 2018;20:520-29. Doi: 10.1111/dom.13103. 37. Terra S.G., Focht K., Davies M., et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diab Obes Metab. 2017;19:721-28. Doi: 10.1111/ dom.12888.
Автор для связи: Мария Сергеевна Новикова, к.м.н., врач-нефролог, Эндокринологический диспансер ДЗМ, Москва, Россия; citrus7474@mail.ru; https://orcid.org/0000-0003-1320-0565